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DNA repair by homologous recombination is involved in
maintaining genome stability. Previous data report that wild-type
p53 suppresses homologous recombination and physically inter-
acts with Rad51. Here, we show the in vivo binding of wild-type
p53 to a p53 response element in the promoter of Rad51 and
the downregulation of Rad51 messenger RNA and protein by
wild-type p53, favoured by DNA damage. Moreover, wild-type
p53 inhibits Rad51 foci formation in response to double-strand
breaks, whereas p53 contact mutant R280K fails to repress Rad51
mRNA and protein expression and Rad51 foci formation. We
propose that transcriptional repression of Rad51 by p53
participates in regulating homologous recombination, and
impaired Rad51 repression by p53 mutants may contribute
to malignant transformation.
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INTRODUCTION
Double-strand breaks (DSBs) are lethal forms of DNA damage and
homologous recombination (HR) is the main error-free DNA
repair mechanism involved (van Gent et al, 2001). Both deficient
and exacerbated HR activity determine genome instability (Tutt
et al, 2001; Richardson et al, 2004), which is directly implicated
in tumour progression (Liu et al, 2004). Rad51 protein has a
central role in DSB repair by HR (Baumann & West, 1998),
forming recombinatory structures known as Rad51 foci (Haaf
et al, 1995; Raderschall et al, 1999). Moreover, Rad51 over-
expression is found in tumours that show increased HR activity
(Vispe et al, 1998). Thus, the requirement for a tight regulation
of Rad51 and HR to maintain genome integrity is generally
accepted (Bertrand et al, 2004).
p53 is the most frequently mutated gene in human cancer
(Greenblatt et al, 1994). It exerts tumour-suppressor activity,
regulating the cell cycle, programmed cell death and DNA
repair. p53 functions are mediated by mechanisms that are
transcriptional (Yu et al, 1999) and non-transcriptional (Mihara
et al, 2003) dependent.
The p53 response to DNA damage involved in tumour
suppression has been related to the activation of DNA repair
mechanisms, such as base excision repair and nucleotide excision
repair (Bernstein et al, 2002). However, p53 also inhibits
inappropriate DNA repair by transactivating the base excision
DNA repair inhibitory phosphatase PPM1D (Lu et al, 2004), and
by negatively regulating key HR proteins such as RAD54 and
RAD51 (Linke et al, 2003). The partial rescue of the lethal
phenotype of Rad51 knockout (KO) mice on a p53-null back-
ground further suggests an interaction between Rad51 and p53
(Shu et al, 1999). Moreover, functional p53 is required to regulate
HR activity, considering that cells harbouring p53 hotspot mutants
show exacerbated HR (Saintigny & Lopez, 2002). Downregulation
of HR activity by p53 has been ascribed to non-transcriptional-
dependent mechanisms, because mutations in the transcriptional
domain of p53 do not affect HR regulation (Bertrand et al, 2004).
However, these p53 mutants were selected on the basis of
impaired transactivation of p53 target genes, but transcriptional
repression remains to be analysed.
In this work, we studied the downregulation of Rad51 by wild
type (wt) p53. We show the transcriptional repression of the
Rad51 gene by p53, which, together with the previously reported
non-transcriptional regulation of RAD51 by p53 (Bertrand et al,
2004; Sengupta & Harris, 2005), may cooperate for efficient
control of HR activity and the maintenance of genomic stability.
RESULTS AND DISCUSSION
Characterization of wt p53 and p53R280K cells
We generated two Tet-Off-inducible cell lines in a p53-null cell
background, expressing wt p53 (p53wt-B2I clone) or the p53
contact mutant p53R280K (p53R280K-A3 clone).
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p53 protein expression was determined in total protein
extracts recovered at different times after tetracycline withdrawal.
As shown in Fig 1A, similar p53 expression was obtained in
p53wt-B2I and p53R280K-A3 clones. p21 protein induction was
analysed to evaluate the transcriptional activity of the p53
proteins; as expected, only wt p53 induces p21 (Fig 1A).
Expression of wt p53 in this cell system induces G1 arrest, as
described previously; however, DNA damage is needed to elicit
a p53-dependent apoptotic response (Baptiste et al, 2002).
Therefore, both cells were X-irradiated, and a sub-diploid
population was induced in the p53wt-B2I cell line (Fig 1B).
Wt p53 downregulates Rad51 messenger RNA and protein
We compared the gene expression patterns of cells expressing wt
p53 and p53R280K to identify novel p53-dependent transcrip-
tional activities. Complementary DNA microarray experiments
were carried out with the Tet-Off-inducible cell lines at different
times after tetracycline removal, and specifically activating p53
with 5-fluorouracil (5FU), an anti-metabolite chemotherapeutic
drug (Baptiste et al, 2002).
We observed that Rad51 mRNA was downregulated 48 h after
wt p53 protein induction (data not shown). To discriminate
whether this effect was due to a gain of function of p53R280K, we
analysed basal Rad51 mRNA levels in the p53-null background
by quantitative reverse transcription–PCR (RT–PCR). As shown in
Fig 1C, wt p53 protein downregulates Rad51 mRNA expression,
whereas similar mRNA levels were obtained in the absence of p53
and with the p53R280K mutant. The reduction of Rad51 mRNA
by 5FU requires wt p53 (Fig 1C), and correlates with a reduction
of Rad51 protein in all conditions tested (Fig 1D).
We then analysed Rad51 regulation by p53wt and its role in
HR repair by treatment with etoposide (VP16), to specifically
induce DSBs (Lundin et al, 2003). As represented in Fig 2A, p53wt
activation by VP16, as shown by induction of the p53 target gene
p21, downregulates Rad51 mRNA and protein levels.
To show that endogenous p53 downregulates Rad51, we
analysed Rad51 mRNA and protein expression in MCF/7 breast
carcinoma cells expressing p53wt. We observed that VP16
treatment reduces Rad51 mRNA and protein expression in
MCF/7 cells, in contrast to MDA-MB-231 breast carcinoma
cells, which express p53R280K mutant protein (Fig 2B). Moreover,
similar results were obtained with HCT116 parental cells
(wt p53) versus the p53 somatic KO isogenic cells when treated
with genotoxic agents. As shown in Fig 2C, induction of DSBs
with doxorubicin significantly reduces both Rad51 mRNA and
protein levels in the HCT116 wt p53 cells when compared with
its p53KO counterpart.
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Fig 1 | Characterization of Tet-Off p53-inducible cell lines. Modulation of
Rad51 by wild-type p53. (A) p53, p21 and tubulin proteins detected with
specific antibodies in the presence of tetracycline (0 h) and at indicated
times after tetracycline removal. (B) Tet-Off-inducible cell lines were
deprived of tetracycline for 28 h, irradiated (10Gy) and recovered 12 h
later. Tetracycline was maintained in control cells (TET). The percentage
of sub-G1 population analysed by flow cytometry (propidium iodide
staining) and representative of three independent experiments is shown.
(C) Data of Rad51 messenger RNA levels by quantitative reverse
transcription–PCR at 48h after tetracycline removal and p53 protein
expression by western blotting in p53wt and p53R280K Tet-Off-inducible
clones. p53 protein expression was induced for 32 h, cells were then treated
with 350mM 5-fluorouracil (5FU) and recovered 16 h later. Tetracycline
was maintained in control cells (TET). Error bars from three independent
experiments are shown. (D) Rad51 protein from samples, treated as in
(C), detected by western blotting. The histogram shows relative Rad51
protein levels normalized by tubulin expression. Relative levels in
histograms (C,D) are calculated considering the maximum value as 100.
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Our results show the transcriptional downregulation of Rad51
by wt p53, which provides another mechanism for controlling
Rad51 activity, and is in agreement with the dual role of p53. Thus,
in response to DNA insult, p53 promotes DNA repair; however, if
severe DNA damage is encountered, it inhibits inconvenient DNA
repair, initiating apoptosis (Zhivotovsky & Kroemer, 2004).
Wt p53 binds to p53RE in the Rad51 promoter
To analyse whether the direct binding of wt p53 to the Rad51
promoter accounts for downregulation of Rad51 mRNA, we
carried out chromatin immunoprecipitation (ChIP) assays, on the
basis of a previous report describing potential p53-responsive
elements in the Rad51 promoter (Wang et al, 2001). As shown in
Fig 3B, wt p53 specifically binds to the Rad51-1 p53-responsive
element, 160 bp upstream of the transcription starting point of the
Rad51 promoter (Fig 3A). In the absence of DNA damage, binding
was observed at 36 h after the removal of tetracycline, decreasing
thereafter (Fig 3B), a result that is in agreement with previous data
reporting the binding of non-activated p53 to chromatin-
assembled promoters (Espinosa & Emerson, 2001). It is possible
that the unusually high p53 protein levels attained in this cell
system (Fig 1A) may account for downregulation of Rad51 in the
absence of damage (Figs 1C,D,2A). However, in p53wt-expressing
MCF/7 and HCT116 tumour cells, Rad51 is only repressed in
response to DNA damage (Fig 2B,C). Finally, binding of p53
to the Rad51 promoter correlates with delayed downregulation
of Rad51 mRNA and protein expression (Fig 2A). In contrast, we
observed that binding of wt p53 to the p21 promoter increases
at 50 h after p53 protein expression, and parallels p21 protein
induction (Figs 2A,3B).
We then studied the effect of DSBs on the in vivo binding of wt
p53 to the Rad51 promoter. VP16 treatment induced sustained
binding of wt p53 to the Rad51 promoter, when compared with
untreated cells (Fig 3B, 50 h), which suggests that p53 activation
by DNA damage may promote the specific binding. Moreover,
this result correlates with the downregulation of Rad51 mRNA and
protein in response to VP16 treatment (Fig 2A). p53 binding to the
p21 promoter and p21 protein induction in response to DNA
damage were increased in all conditions tested (Figs 2A,3B).
Sustained binding of wt p53 to the Rad51 promoter and
concomitant binding to the p21 promoter in response to DSBs
suggest a cooperative cautionary effect between cell-cycle arrest
and inhibition of DNA repair.
To show the regulation of Rad51 by specific binding of p53wt
to the Rad51 promoter, we carried out luciferase reporter assays
with the Rad51-Luc plasmid containing the p53-responsive
element Rad51-1 from the Rad51 promoter. Coexpression of
p53wt and Rad51-Luc resulted in p53-dependent repression of the
reporter gene; however, expression of the contact mutant
p53R280K had no significant effect (Fig 3C). These results were
confirmed by transactivation experiments in which the reporter
gene is mutated at the p53-binding sites of the Rad51 promoter.
p53wt-mediated repression is abolished by deletion of the 42 bp
promoter region containing the p53 response elements. Moreover,
Fig 2 | Wild-type p53 downregulates Rad51 messenger RNA and protein
expression in response to DNA damage. (A) p53wt Tet-Off-inducible cells
were grown for 28 h in the absence of tetracycline and subsequently
treated with 15 mM VP16. RNA and protein extracts were recovered at 36
or 50 h after tetracycline removal. (B) MCF/7 and MDA-MB-231 cells
were treated with VP16 (0, 0.1, 1 and 10mM), and RNA and protein
extracts were recovered at the indicated times. (C) Parental (p53wt) and
somatic p53KO HCT116 cells were treated with 350mM 5-fluorouracil
(5FU), 15 mM VP16 or 0.5mM doxorubicin (Doxo), and RNA and protein
extracts were recovered at the indicated times. In all cases, Rad51 mRNA
was evaluated by quantitative reverse transcription–PCR and relative
RNA levels were obtained considering the maximum value as 100. Error
bars from three experiments are shown. Rad51, p53, p21 and tubulin or
actin proteins were detected by western blotting.
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repression is partially reduced when introducing specific point
mutations of the p53 consensus sequence but preserving the
palindromic structure (Fig 3D).
Gene repression by p53, although poorly understood, is
mediated by different mechanisms (Ho & Benchimol, 2003),
which differ from those required for efficient transactivation, but
are known to be relevant for p53 tumour-suppressor activity
(Kho et al, 2004).
It has been previously reported that repression of HR by p53
is transactivation independent (Dudenhoffer et al, 1999; Willers
et al, 2000; Linke et al, 2003). The transactivation-deficient p53
mutant (22Q, 23S; Lu & Levine, 1995) represses HR activity
(Boehden et al, 2003); interestingly, the mouse homologue (25L,
26W) binds specifically to DNA (Jimenez et al, 2000). Moreover,
transcriptional repression of cdc25c phosphatase by p53 requires
specific DNA binding (St Clair et al, 2004). Thus, binding to
p53REs in promoters or recruitment of transcriptional corepressors
may account for preserved transcriptional repression in otherwise
transactivation-impaired p53 mutants.
Inhibition of Rad51 foci formation by wt p53
Wt p53 inhibits Rad51-mediated HR (Linke et al, 2003; Bertrand
et al, 2004; Yoon et al, 2004) and exacerbated HR is observed
with p53 functional impairment (Saintigny & Lopez, 2002). To
correlate the modulation of Rad51 transcription by p53 with HR
regulation, we analysed Rad51 foci formation in cells expressing
wt p53 or p53R280K mutant proteins in response to DSBs (Ivanov
et al, 2003). As shown in Fig 4A, wt p53 inhibits Rad51 foci
formation when compared with the p53R280K-expressing cells, in
agreement with the downregulation of Rad51 mRNA and protein
induced by wt p53 that we have previously reported (Fig 2A).
Inhibition of Rad51 foci is wt p53 specific because no significant
differences in the S/G2 population were detected (Fig 4B).
We further confirmed the requirement of wt p53 to inhibit
Rad51 foci in HCT116 p53KO versus the p53wt parental cells.
We observed that less Rad51 foci were detected in the p53wt
compared with the p53KO HCT116 cells (Fig 4D). Both cell lines
had similar percentages of S/G2 population, as analysed by flow
cytometry (Fig 4E). The inhibition of Rad51 foci observed in p53wt
HCT116 cells correlates with our results reporting p53-dependent
Rad51 downregulation in this cell line (Fig 2C).
The specific contribution of p53-dependent mechanisms in
repressing HR remains to be established; however, cooperative
efficient repression of HR by p53 may be required. For instance,
p53 interacts with RPA, providing another mechanism of HR
regulation by p53 (Romanova et al, 2004).
We propose a novel wt p53-dependent mechanism that
contributes to controlling HR by downregulating Rad51 transcrip-
tion, as demonstrated by the in vivo binding to a p53RE in the
Rad51 promoter, the reduction of Rad51 mRNA and protein, and
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Fig 3 | Wild-type p53 binds and represses Rad51 promoter. (A) The
162/116 sequence of the Rad51 promoter is shown with quarter sites
in the p53-binding consensus (Rad51-1) indicated by arrows and
deviations from the consensus indicated by underlined lowercase letters.
(B) Chromatin immunoprecipitation (ChIP) assays to amplify fragments
of Rad51 and p21 promoter regions containing the p53REs. p53wt
Tet-Off-inducible cells, grown for 28 h without tetracycline, were
subsequently treated with15mM VP16 and recovered at 36 or 50 h after
tetracycline removal. Input represents specific amplification of sonicated
chromatin before immunoprecipitation. p53-negative experimental
control (TET) was obtained from cells grown with tetracycline.
(C) H1299 cells were transfected with luciferase reporter plasmid
Rad51-luc and p53wt or p53R280K coding plasmids (0, 0.4, 0.8 or 1.6 mg),
and protein extracts were recovered 48 h later. The histogram shows
relative luciferase activity considering the value of cells transfected with
Rad51-luc plasmid alone as 10. Error bars from data of three
experiments are shown. p53 and actin proteins were detected by western
blotting. (D) H1299 cells were transfected with luciferase reporter Rad51-
luc (WT), mutant Rad51-luc (MUT) or deletion mutant Rad51-luc (DEL)
plasmids and p53wt coding plasmid (0 and 0.8mg), and protein extracts
were recovered 48 h later. The histogram shows relative luciferase activity
considering the value in cells transfected with the reporter plasmids
alone as 10. Error bars from data of three experiments are shown.
p53 and actin proteins were detected by western blotting.
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the inhibition of Rad51 foci formation. In this context, the
transcriptional repression of Rad51 by p53 may cooperate with
the previously reported inhibition of Rad51 assembly by p53
(Linke et al, 2003).
It has been suggested that induction of an apoptotic outcome in
cells with abundant DNA damage requires repression of HR
activity (Ivanov et al, 2003), consistent with a potential role of p53
in the tight control of HR. Moreover, Rad51 overexpression
confers radio-resistance to the cell (Collis et al, 2001). These
results thus indicate that the use of combined treatment with
Rad51 inhibitors (Russell et al, 2003) may improve conventional
current tumour therapies by restoring the repression of HR activity,
which is impaired in cancer cells harbouring mutant p53 proteins.
METHODS
Cell lines and plasmids. H24 cells and human wt p53 coding
plasmid pUHD (10-3)-p53 were kindly provided by Dr X. Chen.
R280K p53 mutation on pUHD(10-3)-p53 plasmid was generated
with the QuikChange Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA, USA). Stable clones were obtained, as described
(Niculescu et al, 1998). Growth conditions for HCT116 cell lines
(a gift from Dr Vogelstein) and MDA-MB-231 and MCF/7 cells are
described in the supplementary information online.
The luciferase reporter plasmid (Rad51-Luc) contains the
948/þ 1427 sequence from the human Rad51 promoter up-
stream of the coding region for firefly luciferase (pGL-3 Basic). The
oligonucleotides, cloning strategy and reporter constructs are
described in the supplementary information online.
Cell-cycle analysis. Fixed cells were treated with 0.25mg/ml
RNase A (Boehringer Mannheim, Basel, Switzerland) and 20mg/ml
propidium iodide (PI; Sigma, St Louis, MO, USA). Flow cytometry
analysis was carried out with COULTER EPICS XL (EXPO 32
software), and 10,000 events were collected.
Western blotting. Total protein extract (50 mg) in RIPA lysis buffer
was separated by SDS–polyacrylamide gel electrophoresis and
analysed by western blotting with the following antibodies: anti-
p53 monoclonal antibody (DO-1) and anti-p21 rabbit polyclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
Rad51 rabbit polyclonal antibody (BD-Biosciences, San Jose, CA,
USA), anti-actin monoclonal antibody (clone AC-40) and anti-
tubulin monoclonal antibody (DM-1 A; Sigma).
Quantitative reverse transcription–PCR. For details, see the
supplementary information online.
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Fig 4 | Wild-type p53 inhibits RAD51 foci formation in response to DNA
damage. (A) Tet-Off p53wt- or p53R280K-inducible cell lines were grown
for 24 h in the absence of tetracycline and treated for 8 h with 15mM
VP16. Subsequently, cells were fixed and labelled for DNA (blue) and
Rad51 (red). A total of 100 cells with higher than five Rad51 foci per cell
were analysed by confocal microscopy. Error bars from data of three
separate experiments are shown. (B) Cell-cycle analysis by flow
cytometry of propidium iodide (PI)-stained cells treated and recovered as
in (A). The histogram shows the percentage of S/G2 population and error
bars of data from three experiments. (C) HCT116 cells were treated with
350mM 5-fluorouracil (5FU) for 32 h and Rad51 foci were analysed by
confocal microscopy as in (A). Control cells (untreated) are grown without
5FU. (D) Cell-cycle analysis by flow cytometry of PI-stained cells treated
and recovered as in (C). The percentage of G2/S population is shown.
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Chromatin immunoprecipitation assay. ChIP experiments were
performed according to the protocol of the Chromatin-Immuno-
precipitation Assay Kit (Upstate Biotechnology, Charlottesville,
VA, USA), with minor modifications. Detailed procedure and
primers are provided in the supplementary information online.
Analysis of Rad51 foci formation. Fixed cells were stained with
an anti-Rad51 antibody (1:100; BD Pharmingen, San Diego, CA,
USA) and incubated with Alexa 555-conjugated goat anti-rabbit
IgG (1:1,000). Nuclei were visualized with TOPRO-3 iodide
(1:10,000; Molecular Probes, Eugene, OR, USA). Images were
obtained with a Leica TCS-SP2 confocal microscope. See the
supplementary information online.
Luciferase reporter assays. See the supplementary information online.
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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